[go: up one dir, main page]

HRP20181774T1 - Novi citostatski 7-deazapurinski nukleosidi - Google Patents

Novi citostatski 7-deazapurinski nukleosidi

Info

Publication number
HRP20181774T1
HRP20181774T1 HRP20181774TT HRP20181774T HRP20181774T1 HR P20181774 T1 HRP20181774 T1 HR P20181774T1 HR P20181774T T HRP20181774T T HR P20181774TT HR P20181774 T HRP20181774 T HR P20181774T HR P20181774 T1 HRP20181774 T1 HR P20181774T1
Authority
HR
Croatia
Prior art keywords
deazapurine nucleosides
novel cytostatic
cytostatic
novel
deazapurine
Prior art date
Application number
HRP20181774TT
Other languages
English (en)
Inventor
Michal Hocek
Petr Naus
Original Assignee
Institute Of Organic Chemistry And Biochemistry Of The Academy Of Sciences Of The Czech Republic
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Institute Of Organic Chemistry And Biochemistry Of The Academy Of Sciences Of The Czech Republic filed Critical Institute Of Organic Chemistry And Biochemistry Of The Academy Of Sciences Of The Czech Republic
Publication of HRP20181774T1 publication Critical patent/HRP20181774T1/hr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/14—Pyrrolo-pyrimidine radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • H—ELECTRICITY
    • H02—GENERATION; CONVERSION OR DISTRIBUTION OF ELECTRIC POWER
    • H02J—CIRCUIT ARRANGEMENTS OR SYSTEMS FOR SUPPLYING OR DISTRIBUTING ELECTRIC POWER; SYSTEMS FOR STORING ELECTRIC ENERGY
    • H02J7/00—Circuit arrangements for charging or depolarising batteries or for supplying loads from batteries
    • H02J7/00032—Circuit arrangements for charging or depolarising batteries or for supplying loads from batteries characterised by data exchange
    • H02J7/00036—Charger exchanging data with battery
    • H—ELECTRICITY
    • H02—GENERATION; CONVERSION OR DISTRIBUTION OF ELECTRIC POWER
    • H02J—CIRCUIT ARRANGEMENTS OR SYSTEMS FOR SUPPLYING OR DISTRIBUTING ELECTRIC POWER; SYSTEMS FOR STORING ELECTRIC ENERGY
    • H02J7/00—Circuit arrangements for charging or depolarising batteries or for supplying loads from batteries
    • H02J7/00047—Circuit arrangements for charging or depolarising batteries or for supplying loads from batteries with provisions for charging different types of batteries

Landscapes

  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Power Engineering (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
HRP20181774TT 2008-01-18 2018-10-29 Novi citostatski 7-deazapurinski nukleosidi HRP20181774T1 (hr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US2224708P 2008-01-18 2008-01-18
EP16174985.8A EP3133080B1 (en) 2008-01-18 2009-01-15 Novel cytostatic 7-deazapurine nucleosides

Publications (1)

Publication Number Publication Date
HRP20181774T1 true HRP20181774T1 (hr) 2018-12-28

Family

ID=40434932

Family Applications (2)

Application Number Title Priority Date Filing Date
HRP20161344TT HRP20161344T1 (hr) 2008-01-18 2009-01-15 Novi citostatski 7-deazapurinski nukleozidi
HRP20181774TT HRP20181774T1 (hr) 2008-01-18 2018-10-29 Novi citostatski 7-deazapurinski nukleosidi

Family Applications Before (1)

Application Number Title Priority Date Filing Date
HRP20161344TT HRP20161344T1 (hr) 2008-01-18 2009-01-15 Novi citostatski 7-deazapurinski nukleozidi

Country Status (18)

Country Link
US (1) US8093226B2 (hr)
EP (2) EP2231689B1 (hr)
JP (2) JP5485172B2 (hr)
CN (1) CN101977923B (hr)
AU (1) AU2009204568B2 (hr)
CA (1) CA2711384C (hr)
CY (2) CY1118104T1 (hr)
DK (2) DK3133080T3 (hr)
ES (2) ES2693551T3 (hr)
HR (2) HRP20161344T1 (hr)
HU (2) HUE041598T2 (hr)
LT (2) LT2231689T (hr)
NZ (1) NZ586610A (hr)
PL (2) PL3133080T3 (hr)
PT (2) PT2231689T (hr)
SI (2) SI3133080T1 (hr)
TR (1) TR201815961T4 (hr)
WO (1) WO2009089804A1 (hr)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007070514A1 (en) 2005-12-13 2007-06-21 Incyte Corporation Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as janus kinase inhibitors
SI3070090T1 (sl) 2007-06-13 2019-04-30 Incyte Holdings Corporation Uporaba soli zaviralca Janus kinaze (R)-3-(4-(7H-pirolo (2,3-D)pirimidin-4-il)-1H-pirazol-1-il)-3-ciklopentilpropannitrila
CL2009001884A1 (es) * 2008-10-02 2010-05-14 Incyte Holdings Corp Uso de 3-ciclopentil-3-[4-(7h-pirrolo[2,3-d]pirimidin-4-il)-1h-pirazol-1-il)propanonitrilo, inhibidor de janus quinasa, y uso de una composición que lo comprende para el tratamiento del ojo seco.
DK2421879T3 (da) * 2009-04-22 2013-11-25 Acad Of Science Czech Republic Nye 7-deazapurinnukleotider til terapeutiske anvendelser
SG176111A1 (en) * 2009-05-22 2011-12-29 Incyte Corp 3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl]octane- or heptane-nitrile as jak inhibitors
NZ596479A (en) 2009-05-22 2014-01-31 Incyte Corp N-(hetero)aryl-pyrrolidine derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines and pyrrol-3-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors
TW201113285A (en) 2009-09-01 2011-04-16 Incyte Corp Heterocyclic derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors
AU2011224484A1 (en) 2010-03-10 2012-09-27 Incyte Holdings Corporation Piperidin-4-yl azetidine derivatives as JAK1 inhibitors
MY161078A (en) 2010-05-21 2017-04-14 Incyte Holdings Corp Topical formulation for a jak inhibitor
BR112013011689A2 (pt) * 2010-11-18 2017-10-17 Kasina Laila Innova Pharmaceuticals Private Ltd compostos e métodos de uso do 4-(selenofeno-2(ou 3)-ilamino) pirimidina substituído
CA2818545C (en) 2010-11-19 2019-04-16 Incyte Corporation Heterocyclic-substituted pyrrolopyridines and pyrrolopyrimidines as jak inhibitors
PE20140146A1 (es) 2010-11-19 2014-02-06 Incyte Corp Derivados de pirrolopiridina y pirrolopirimidina sustituidos con ciclobutilo como inhibidores de jak
WO2012177606A1 (en) 2011-06-20 2012-12-27 Incyte Corporation Azetidinyl phenyl, pyridyl or pyrazinyl carboxamide derivatives as jak inhibitors
TW201313721A (zh) 2011-08-18 2013-04-01 Incyte Corp 作為ｊａｋ抑制劑之環己基氮雜環丁烷衍生物
UA111854C2 (uk) 2011-09-07 2016-06-24 Інсайт Холдінгс Корпорейшн Способи і проміжні сполуки для отримання інгібіторів jak
WO2013173720A1 (en) 2012-05-18 2013-11-21 Incyte Corporation Piperidinylcyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as jak inhibitors
SMT202100436T1 (it) 2012-11-15 2021-09-14 Incyte Holdings Corp Forme di dosaggio a rilascio prolungato di ruxolitinib
UA121532C2 (uk) 2013-03-06 2020-06-10 Інсайт Холдінгс Корпорейшн Способи і проміжні сполуки при отриманні інгібітора jak
SG10201912203XA (en) 2013-08-07 2020-02-27 Incyte Corp Sustained release dosage forms for a jak1 inhibitor
WO2015184305A1 (en) 2014-05-30 2015-12-03 Incyte Corporation TREATMENT OF CHRONIC NEUTROPHILIC LEUKEMIA (CNL) AND ATYPICAL CHRONIC MYELOID LEUKEMIA (aCML) BY INHIBITORS OF JAK1
CA3029170C (en) 2016-06-29 2021-02-16 Ustav Organicke Chemie A Biochemie Av Cr, V.V.I. Substituted thienopyrrolopyrimidine ribonucleosides for therapeutic use
CZ307334B6 (cs) 2016-08-02 2018-06-13 Ăšstav organickĂ© chemie a biochemie AV ÄŚR, v.v.i. Substituované heteropentadieno-pyrrolopyrimidinové ribonukleosidy pro terapeutické použití
AR113922A1 (es) 2017-12-08 2020-07-01 Incyte Corp Terapia de combinación de dosis baja para el tratamiento de neoplasias mieloproliferativas
PL3746429T3 (pl) 2018-01-30 2022-06-20 Incyte Corporation Procesy do otrzymywania (1-(3-fluoro-2-(trifluorometylo)izonikotynoilo)piperydyn-4-onu)
CZ308104B6 (cs) 2018-03-12 2020-01-08 Ăšstav organickĂ© chemie a biochemie AV ÄŚR, v. v. i. Pyridinopyrrolopyrimidinové ribonukleosidy pro terapeutické použití
PE20210402A1 (es) 2018-03-30 2021-03-02 Incyte Corp Tratamiento de la hidradenitis supurativa mediante el uso de inhibidores de jak
US20220152072A1 (en) * 2019-04-05 2022-05-19 Prelude Therapeutics, Incorporated Selective Inhibitors Of Protein Arginine Methyltransferase 5 (PRMT5)
WO2020255979A1 (ja) * 2019-06-18 2020-12-24 大鵬薬品工業株式会社 ピロロピリミジン骨格を有する新規なカーボネート化合物又はその薬学的に許容可能な塩
WO2021164848A1 (en) * 2020-02-17 2021-08-26 Katholieke Universiteit Leuven Novel 6-substituted 7-deazapurines and corresponding nucleosides as medicaments
US11833155B2 (en) 2020-06-03 2023-12-05 Incyte Corporation Combination therapy for treatment of myeloproliferative neoplasms
CN112190590A (zh) * 2020-11-06 2021-01-08 牡丹江医学院 一种治疗动脉粥样硬化的硒核苷及其药物组合物

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS50125033A (hr) * 1974-03-19 1975-10-01
IL108523A0 (en) * 1993-02-03 1994-05-30 Gensia Inc Pharmaceutical compositions containing adenosine kinase inhibitors for preventing or treating conditions involving inflammatory responses and pain
JPH10158293A (ja) * 1996-08-08 1998-06-16 Rikagaku Kenkyusho ３’−デオキシリボヌクレオチド誘導体
JP3318579B2 (ja) * 1997-07-07 2002-08-26 理化学研究所 Ｄｎａの塩基配列決定方法
JP3489991B2 (ja) * 1997-07-07 2004-01-26 理化学研究所 ３’−デオキシリボヌクレオチド誘導体
CZ9901996A3 (cs) * 1999-06-04 2001-01-17 Ústav organické chemie a biochemie AV ČR Nové 6-fenylpurinové 9-ß-D-ribonukleosidy s antineoplastickým účinkem, jejich použití k přípravě farmaceutických preparátů a farmaceutické přípravky, které je obsahují
AU2002353165A1 (en) * 2001-12-17 2003-06-30 Ribapharm Inc. Deazapurine nucleoside libraries and compounds
RU2006109491A (ru) * 2003-08-27 2006-08-10 Байота, Инк. (Au) Новые трициклические нуклеозиды или нуклеотиды в качестве терапевтических средств
CN101043893A (zh) * 2004-10-21 2007-09-26 默克公司 治疗RNA－依赖性RNA病毒感染的氟化吡咯并[2,3－d]嘧啶核苷
US20080280842A1 (en) * 2004-10-21 2008-11-13 Merck & Co., Inc. Fluorinated Pyrrolo[2,3-D]Pyrimidine Nucleosides for the Treatment of Rna-Dependent Rna Viral Infection
US7405204B2 (en) * 2005-04-25 2008-07-29 Genelabs Technologies, Inc. Nucleoside compounds for treating viral infections

Also Published As

Publication number Publication date
PT2231689T (pt) 2016-10-07
CA2711384C (en) 2016-07-26
ES2598503T3 (es) 2017-01-27
EP3133080A1 (en) 2017-02-22
CY1121364T1 (el) 2020-05-29
EP2231689B1 (en) 2016-07-20
PT3133080T (pt) 2018-11-16
AU2009204568A1 (en) 2009-07-23
ES2693551T3 (es) 2018-12-12
CA2711384A1 (en) 2009-07-23
US8093226B2 (en) 2012-01-10
SI3133080T1 (sl) 2018-12-31
JP5485172B2 (ja) 2014-05-07
CY1118104T1 (el) 2017-06-28
DK2231689T3 (en) 2016-09-19
WO2009089804A1 (en) 2009-07-23
PL2231689T3 (pl) 2017-01-31
CN101977923B (zh) 2014-10-08
LT3133080T (lt) 2018-11-12
HUE030767T2 (en) 2017-05-29
HUE041598T2 (hu) 2019-05-28
JP2014058567A (ja) 2014-04-03
LT2231689T (lt) 2016-10-25
AU2009204568B2 (en) 2013-10-03
TR201815961T4 (tr) 2018-11-21
EP2231689A1 (en) 2010-09-29
NZ586610A (en) 2012-08-31
DK3133080T3 (en) 2018-11-26
US20090203637A1 (en) 2009-08-13
CN101977923A (zh) 2011-02-16
PL3133080T3 (pl) 2018-12-31
JP2011509949A (ja) 2011-03-31
HRP20161344T1 (hr) 2016-11-18
SI2231689T1 (sl) 2016-11-30
EP3133080B1 (en) 2018-08-01

Similar Documents

Publication Publication Date Title
HRP20181774T1 (hr) Novi citostatski 7-deazapurinski nukleosidi
ZA201101104B (en) Novel adenine derivatives
ZA201008829B (en) Nucleoside cyclicphosphates
SI2421879T1 (sl) Novi 7-deazapurinski nukleozidi za terapevtske uporabe
IL213698A0 (en) Nucleoside phosphoramidates
ZA201104638B (en) Nucleoside analogs
IL200831A0 (en) Novel adenine compounds
IL205625A0 (en) Antiviral nucleoside compounds
EP2138497A4 (en) NEW ADENINE CONNECTION
IL213701A0 (en) Synthesis of purine nucleosides
IL210207A0 (en) Compounds having antiviral properties
ZA201103943B (en) Purine compounds
GB0803707D0 (en) Antiviral agent
GB0723609D0 (en) Antiviral
HK1149016A (en) Novel cytostatic 7-deazapurine nucleosides
IL207312A0 (en) Cytostatic composition
GB0816600D0 (en) Antiviral compounds
GB0819528D0 (en) Antiviral compounds
IL192335A0 (en) Antiviral compounds
GB0704852D0 (en) Furanose derivatives
GB0717955D0 (en) Preparation of modified nucleosides
GB0803654D0 (en) Buster brackets (KA-2 + KA-9)
GB0819857D0 (en) Antiviral therapy